India, Nov. 11 -- TriSalus Life Sciences, Inc. (TLSI), on Tuesday reported third-quarter 2026 financial results, with revenue increasing 11.3% year over year to $12.9 million.
The company highlighted FDA clearance for TriNav Advance and expanded Medicare reimbursement policies for procedures using its Pressure-Enabled Drug Delivery (PEDD) technology. TriSalus also revised its full-year 2026 revenue guidance to $46 million to $48 million.
Company Profile
TriSalus Life Sciences is an oncology company integrating novel drug-delivery technology with standard-of-care therapies and investigational immunotherapies to improve treatment for patients with solid tumors.
Q3 2026 Financial Highlights
For the quarter ended September 30, 2026, revenu...